Covid may have accelerated the evolution, but changes to diligence, value creation and exit strategies were already afoot, says WilliamsMarston partner Jon Marston.
Linden Capital Partners on why healthcare CVs are gaining traction
1 October 2026 · 5 mins read
McDermott on preparing for exit in a selective M&A market
21 September 2026 · 5 mins read
Taproot Capital on understanding the seeding opportunity for spin-outs
14 September 2026 · 6 mins read
Simpson Thacher & Bartlett on how buyside expansion fuels dealflow
1 June 2026 · 7 mins read
W Capital Partners on why secondaries is now core to PE portfolio management
1 June 2026 · 5 mins read
Fried Frank on the next step for CVs
1 June 2026 · 8 mins read
Dawson Partners on predicting a $300bn year for secondaries
1 June 2026 · 5 mins read
